Logo image of SLNO

SOLENO THERAPEUTICS INC (SLNO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SLNO - US8342033094 - Common Stock

51.37 USD
-1.31 (-2.49%)
Last: 12/5/2025, 8:00:02 PM
51.37 USD
0 (0%)
After Hours: 12/5/2025, 8:00:02 PM
Fundamental Rating

3

SLNO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. While SLNO seems to be doing ok healthwise, there are quite some concerns on its profitability. SLNO has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year SLNO has reported negative net income.
SLNO had a negative operating cash flow in the past year.
In the past 5 years SLNO always reported negative net income.
In the past 5 years SLNO always reported negative operating cash flow.
SLNO Yearly Net Income VS EBIT VS OCF VS FCFSLNO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

With an excellent Return On Assets value of -13.08%, SLNO belongs to the best of the industry, outperforming 82.06% of the companies in the same industry.
With an excellent Return On Equity value of -15.85%, SLNO belongs to the best of the industry, outperforming 85.61% of the companies in the same industry.
Industry RankSector Rank
ROA -13.08%
ROE -15.85%
ROIC N/A
ROA(3y)-55.18%
ROA(5y)-58.08%
ROE(3y)-109.68%
ROE(5y)-111.38%
ROIC(3y)N/A
ROIC(5y)N/A
SLNO Yearly ROA, ROE, ROICSLNO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SLNO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLNO Yearly Profit, Operating, Gross MarginsSLNO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

5

2. Health

2.1 Basic Checks

SLNO has more shares outstanding than it did 1 year ago.
SLNO has more shares outstanding than it did 5 years ago.
SLNO has a worse debt/assets ratio than last year.
SLNO Yearly Shares OutstandingSLNO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
SLNO Yearly Total Debt VS Total AssetsSLNO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

SLNO has an Altman-Z score of 15.32. This indicates that SLNO is financially healthy and has little risk of bankruptcy at the moment.
SLNO has a better Altman-Z score (15.32) than 86.73% of its industry peers.
SLNO has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.10, SLNO is doing worse than 64.30% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z 15.32
ROIC/WACCN/A
WACCN/A
SLNO Yearly LT Debt VS Equity VS FCFSLNO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 16.08 indicates that SLNO has no problem at all paying its short term obligations.
The Current ratio of SLNO (16.08) is better than 92.71% of its industry peers.
SLNO has a Quick Ratio of 15.88. This indicates that SLNO is financially healthy and has no problem in meeting its short term obligations.
SLNO has a Quick ratio of 15.88. This is amongst the best in the industry. SLNO outperforms 92.71% of its industry peers.
Industry RankSector Rank
Current Ratio 16.08
Quick Ratio 15.88
SLNO Yearly Current Assets VS Current LiabilitesSLNO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

SLNO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.58%, which is quite impressive.
EPS 1Y (TTM)44.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125.68%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 52.85% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y96.75%
EPS Next 2Y70.34%
EPS Next 3Y52.85%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLNO Yearly Revenue VS EstimatesSLNO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2025 2026 2027 200M 400M 600M
SLNO Yearly EPS VS EstimatesSLNO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -50 -100 -150

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

SLNO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
SLNO is valuated correctly with a Price/Forward Earnings ratio of 13.38.
97.01% of the companies in the same industry are more expensive than SLNO, based on the Price/Forward Earnings ratio.
SLNO is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.69, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 13.38
SLNO Price Earnings VS Forward Price EarningsSLNO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLNO Per share dataSLNO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as SLNO's earnings are expected to grow with 52.85% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y70.34%
EPS Next 3Y52.85%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SLNO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOLENO THERAPEUTICS INC

NASDAQ:SLNO (12/5/2025, 8:00:02 PM)

After market: 51.37 0 (0%)

51.37

-1.31 (-2.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners125.09%
Inst Owner Change15.04%
Ins Owners1.48%
Ins Owner Change1.38%
Market Cap2.76B
Revenue(TTM)98.67M
Net Income(TTM)-78.45M
Analysts86.32
Price Target115.81 (125.44%)
Short Float %18.46%
Short Ratio4.97
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)419.9%
Min EPS beat(2)80.77%
Max EPS beat(2)759.03%
EPS beat(4)2
Avg EPS beat(4)207.86%
Min EPS beat(4)-7.96%
Max EPS beat(4)759.03%
EPS beat(8)3
Avg EPS beat(8)72.02%
EPS beat(12)5
Avg EPS beat(12)44.04%
EPS beat(16)8
Avg EPS beat(16)37.6%
Revenue beat(2)2
Avg Revenue beat(2)30.96%
Min Revenue beat(2)27.34%
Max Revenue beat(2)34.57%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.59%
PT rev (3m)-4.27%
EPS NQ rev (1m)28.08%
EPS NQ rev (3m)188.94%
EPS NY rev (1m)81.88%
EPS NY rev (3m)86.9%
Revenue NQ rev (1m)10.08%
Revenue NQ rev (3m)32.63%
Revenue NY rev (1m)25.66%
Revenue NY rev (3m)27.71%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 13.38
P/S 27.96
P/FCF N/A
P/OCF N/A
P/B 5.58
P/tB 5.64
EV/EBITDA N/A
EPS(TTM)-1.84
EYN/A
EPS(NY)3.84
Fwd EY7.48%
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS1.84
BVpS9.21
TBVpS9.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -13.08%
ROE -15.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.18%
ROA(5y)-58.08%
ROE(3y)-109.68%
ROE(5y)-111.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.14%
Cap/Sales 0.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.08
Quick Ratio 15.88
Altman-Z 15.32
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)3.83%
Cap/Depr(5y)2.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125.68%
EPS Next Y96.75%
EPS Next 2Y70.34%
EPS Next 3Y52.85%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y37.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year105.97%
EBIT Next 3Y70.33%
EBIT Next 5YN/A
FCF growth 1Y-9.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.95%
OCF growth 3YN/A
OCF growth 5YN/A

SOLENO THERAPEUTICS INC / SLNO FAQ

What is the ChartMill fundamental rating of SOLENO THERAPEUTICS INC (SLNO) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SLNO.


What is the valuation status for SLNO stock?

ChartMill assigns a valuation rating of 4 / 10 to SOLENO THERAPEUTICS INC (SLNO). This can be considered as Fairly Valued.


How profitable is SOLENO THERAPEUTICS INC (SLNO) stock?

SOLENO THERAPEUTICS INC (SLNO) has a profitability rating of 2 / 10.


What is the expected EPS growth for SOLENO THERAPEUTICS INC (SLNO) stock?

The Earnings per Share (EPS) of SOLENO THERAPEUTICS INC (SLNO) is expected to grow by 96.75% in the next year.